Data Fields

The Following list shows the data that is available to approved research projects in addition to the Epidemiology Questionnaire

Table	Field	Description	Available values
BloodSpecimen	DateTaken	Date the blood was drawn from the participant
BloodSpecimen	NonBloodType	Sample type collected if not blood (usually mouthwash)
BloodSpecimen	CurrentlyPregnant	Was the participant pregnant at the time the blood was taken
BloodSpecimen	DateLastMenstrual	Date of last menstrual period when blood was taken
BloodSpecimen	AveDaysMenstrualCycle	Average number of days of menstrual cycle for participant
BloodSpecimen	Menopause	Had the participant reached menopause at the time the blood was taken
BloodSpecimen	OCP	Was the participant taking the oral contraceptive pill at the time the blood was taken
Cancer	CancerSite	Site of cancer
Cancer	Laterality	Laterality of cancer	Bilateral Left Right Unknown
Cancer	Diagnosed	Date diagnosed
Cancer	DiagnosedApprox	Was diagnosis date approximate
Cancer	DiagnosisDateUnknown	Diagnosis date not able to determined (Diagnosed will not be given if this field is true)
Cancer	VerificationOutcome	Was the cancer able to be verified
Death	CancerCause	Did the participant die from cancer
Death	CancerSite	Site of the cancer that contributed to the participant's death
Family	UFN	Unique family ID
Family	CriteriaOnEntry	Straddie criteria the family was recruited on
Family	FamilyReviewDate	Date at last family review
Family	CriteriaOnReview	Straddie criteria at last review
FamilyMutation	Nomenclature	Description of classified mutation
FamilyMutation	Gene	Gene of classified mutation
FamilyMutation	MutationEffect	Effect of classified mutation	Pathogenic (P) Splice Site (Sp) Large genomic rearrangement (LGR) Unclassified variant (UV) Likely to be pathogenic (UVP) Low clinical significance (LCS) Polymorphism (PM)
Haplotype BRCA1	UFN	Family number
Haplotype BRCA1	Kindred type	Kindred type
Haplotype BRCA1	BRCA1 shared/typed	BRCA1 shared/typed
Haplotype BRCA1	Date	Date tested
Haplotype BRCA1 and BRCA2	UFN	Family number
Haplotype BRCA1 and BRCA2	Kindred type	Kindred type
Haplotype BRCA1 and BRCA2	BRCA1 shared/typed	BRCA1 shared/typed
Haplotype BRCA1 and BRCA2	Date	Date tested
Haplotype BRCA2	UFN	Family number
Haplotype BRCA2	Kindred type	Kindred type
Haplotype BRCA2	BRCA2 shared/typed	BRCA2 shared/typed
Haplotype BRCA2	Date	Date tested
Haplotype Neither	UFN	Family number
Haplotype Neither	Kindred type	Kindred type
Haplotype Neither	Date	Date tested
Mutation	Report Date	Date the mutatation was reported
Mutation	Gene	Gene tested
Mutation	MutationResult	Result of the mutation test (positive or negative)
Mutation	ResultType	Diagnostic (clinical) or research (kconfab) mutation test
Mutation	TestMethod	The method used for the test
Mutation	Predictive	Was the test a predictive test
Mutation	FullScreen	Was the whole gene tested
Mutation	Exon13	Was Exon 13 tested
Mutation	LargeDeletion	Was the test a search for a large deletion
Mutation	MutationDesc	Description of the mutation as given by the testing laboratory
Mutation	FamilyMutation	Link to the Family mutation the test relates to
Pathology	Prophylactic	Was the procedure for prophylactic treatment
Pathology	Side	Side of the body the tissue was taken from
Pathology	Report Date	Date the report was generated by the pathology laboratory
Pathology	PathologyProcedure	Procedure that extracted the sample that was tested
Pathology	PathSampleType	Type of tissue that was extracted	Archival block Archival tissue Ascites Fresh tissue Pleural effusion RNA later Shavings Slide - stained Slide - unstained
Pathology	Tumour	Did the tested sample contain tumour	Biopsy Biopsy - sentinal node clearing Biopsy - sentinal node sampling Curettings Ductal lavage Excision FNA Hysterectomy Hysterosalpingectomy Lumpectomy Lumpectomy with axillary Mastectomy Mastectomy, left radical Mastectomy, left, modified radical Mastectomy, right radical Mastectomy, right modified radical Oophorectomy Prostatectomy Salpingo-oophorectomy Simple mastectomy Tap
Pathology	TumourSize	Size of tumour found
Pathology	Topography	Topography classification (ICD-O description)
Pathology	Morphology	Morphology classification (ICD-O description)
Pathology	Behaviour	Behaviour classification	Benign Carcinoma in situ Malignant, metastatic site Malignant, primary site Malignant, uncertain prim or met Micro-invasive Uncertain whether benign or malig
Pathology	Grade	Grade classification
Pathology	Oestrogen	Oestrogen receptor test result
Pathology	Progesterone	Progesterone receptor test result
Pathology	CA125	CA125 test result
Pathology	HER2	HER2 test result
Pathology	PSA	PSA test result
Pathology	Gleason	Gleason score
Pathology	NodesTested	Number of lymph nodes tested	if blank then not detailed in report
Pathology	NodesPositive	Number of positive lymph nodes
Pathology	DCISMorphology	Morphology of any in-situ carcinoma found in addition to invasive
Pathology	DCISGrade	Grade of any in-situ carcinoma found in addition to invasive
PathologyReview	ReviewDate	Date of the pathology review
PathologyReview	SourceLab	Pathology laboratory who generated the original pathology report
PathologyReview	TumourSize	Tumour diameter recorded on report (mm)
PathologyReview	HR	Were hormone receptor tested
PathologyReview	HRMethod	Method used to test the hormone receptors	IHC EIA Other
PathologyReview	ER	Oestrogen receptor “Positive” or “Negative” and quantitative result (if supplied)
PathologyReview	PR	Progesterone receptor “Positive” or “Negative” and quantitative result (if supplied)
PathologyReview	LNNumber	Number of lymph nodes identified
PathologyReview	MetNum	Number of lymph nodes containing metastases
PathologyReview	SentinalSelect	Staining results for sentinal nodes	Negative H+E positive IHC positive H+E and IHC positive
Pathology review has been performed only on 214 slide review samples
Person	UPN	Unique person ID
Person	Gender	Gender of participant
Person	StartDate	Date the participant's details were added to the database
Person	DOB	Date of birth of the participant
Person	DOBUnknown	Is the date of birth approximate
Person	DeathDate	Date of death of the participant
Person	DeathDateApprox	Is the date of death approximate
Person	NoFamilyHistory	The participant has no family history of their own
PersonOtherStudy	OtherStudy	Description of other study the participant is enrolled in
PersonRelation	ParentID	ID of the participant's parents
Family pedigrees are also available in .jpg or Progeny format
QANormalBreast	ArchPattern	Silverberg architectural pattern
QANormalBreast	NuclearPleo	Silverberg nuclear pleopmorphism
QANormalBreast	Mitotic	Silverberg mitotic activity
QANormalBreast	Cellularity	Silverberg cellularity
QANormalBreast	Neoplastic	% neoplastic component	0% 1-25% 25-50% 50-75% 75-100%
QANormalBreast	Lymph	Non-neoplastic component: % lymph	0% 1-25% 25-50% 50-75% 75-100%
QANormalBreast	Stroma	Non-neoplastic component: % stroma	0% 1-25% 25-50% 50-75% 75-100%
QANormalBreast	NormalType1Percent	Normal epithelium component: % type 1	0% 1-25% 25-50% 50-75% 75-100%
QANormalBreast	NormalType2Percent	Normal epithelium component: % type 2	0% 1-25% 25-50% 50-75% 75-100%
QANormalBreast	Necrotic	% necrotic component	0% 1-25% 25-50% 50-75% 75-100%
QANormalBreast	Morphology	Morphology description
QANormalBreast records QA results for normal (prophylactic) breast tissue.
QANormalOvary	Side	Tissue laterality
QANormalOvary	SurfaceEpi	Presence of surface epithelium
QANormalOvary	EpiAmount	Amount of surface epithelium	Scant Moderate Abundant
QANormalOvary	Pappilations	Presence of surface epithelium papillations
QANormalOvary	PapAmount	Amount of epithilium papillations	Scant Moderate Abundant
QANormalOvary	Cysts	Presence of epithelial inclusion cysts
QANormalOvary	CystAmount	Amount of epithilial cysts	Scant Moderate Abundant
QANormalOvary	Invaginations	Presence of cortical invaginations
QANormalOvary	InvagAmount	Amount of cortical invaginations	Scant Moderate Abundant
QANormalOvary	Stroma	Presence of stroma
QANormalOvary	Follicles	Presence of cortext follicles
QANormalOvary	CorpLutea	Presence of cortex corpora lutea
QANormalOvary	FollCysts	Presence of follicular cysts
QANormalOvary	Rete	Presence of rete ovarii
QANormalOvary	Fallopian	Presence of fallopian tube
QANormalOvary	Morphology	Preservation of morphology	Well preserved Moderate preservation Poor preservation
QANormalOvary	%Tumour	% tumour in sample
QANormalOvary records QA results for normal (prophylactic) ovarian tissue
QAProstate	Lab	Pathology laboratory from which the slide was sourced
QAProstate	Histology	Prostate histology	Adenocarcinoma Adenocarcinoma variants (specify) Other (specify)
QAProstate	SpecimenType	Specimen type	Radical prostatectomy TURP Prostate needle biopsy Other (specify)
QAProstate	SpecimenBiopsyCores	If specimen type is biopsy; the number of cores
QAProstate	SpecimenBiopsyCoresTumour	If specimen type is biopsy; the number of cores with tumour
QAProstate	TumourVolume	Tumour Volume	Minimal Moderate Extensive
QAProstate	GleasonScore1	Gleason score: primary pattern
QAProstate	GleasonScore2	Gleason score: secondary pattern
QAProstate	PrimaryTumour	If no tumour	Cannot be assessed No tumour
QAProstate	PrimaryTumourT1	Extent of clinically inapparent tumour	Incidental <=5% Incidental >5% Identified by needle biopsy
QAProstate	PrimaryTumourT2	Extent of tumour confined within prostate	<=50% one lobe >50% one lobe both lobes
QAProstate	PrimaryTumourT3	Tumour extends through prostate capsule	Extracapsular extension Invades seminal vesicle
QAProstate	PrimaryTumourT4	Tumour is fixed or invades adjacent structures
QAProstate	RegionalNodes	Status of regional lymph nodes	Not assessed No metastasis Met in regional lymph nodes
QAProstate	DistantMetastasis	Distant metastasis	Cannot be assessed No distant metastasis Distant metastasis
QAProstate	ResectionMargins	Involvement of resection margins
QAProstate	Extra-prostatic extension	Extent of extra-prostatic extension	Focal Established
QAProstate	PerineuralInvasion	Presence of perineural invasion
QAProstate	NeurovascularBundles	Involvement of neurovascular bundles
QAProstate	Lymphovascular invasion	Presence of lymphovascular invasion
QAProstate	NeuroendocrineFeatures	Presence of neuroendocrine features
QAProstate	IntraEpithelialNeoplasia	Presence of high grade prostatic intraepithelial neoplasia
QAProstate	OtherFeatures	Any other histological features	Acute inflammation Chronic inflammation Benign prostatic hyperplasia Other (specify)
QAProstate records QA results for prostate tissue
QATumour	TissueType	Type of tissue QA'd
QATumour	Grade	Tumour grade	Well differentiated Moderately differentiated Poorly differentiated Undifferentiated Not determined / stated
QATumour	ArchPattern	Silverberg architectural pattern (ovary only)
QATumour	NuclearPleo	Silverberg nuclear pleopmorphism (ovary only)
QATumour	Mitotic	Silverberg mitotic activity (ovary only)
QATumour	Neoplastic	% neoplastic component	0% 1-25% 25-50% 50-75% 75-100%
QATumour	Lymph	Non-neoplastic component: % lymph	0% 1-25% 25-50% 50-75% 75-100%
QATumour	Stroma	Non-neoplastic component: % stroma	0% 1-25% 25-50% 50-75% 75-100%
QATumour	NormalType1Percent	Normal component: % type 1	0% 1-25% 25-50% 50-75% 75-100%
QATumour	NormalType2Percent	Normal component: % type 2	0% 1-25% 25-50% 50-75% 75-100%
QATumour	Necrotic	% necrotic component	0% 1-25% 25-50% 50-75% 75-100%
QATumour	Morphology	Morphology description
QATumour	BRCAXReview	BRCA-like features (breast only)	BRCA1-like BRCA2-like Indeterminate
QATumour records QA results for tumour tissue (not just breast)
SlideReview	SourceLab	Pathology laboratory from which the slide was sourced
SlideReview	AccessionNumber	Laboratory accession number
SlideReview	SlidesExamined	Which slides were examined
SlideReview	ObsDate	Review date
SlideReview	HistoSubType	Histological subtype of invasive carcinoma	Ductal / not special type Lobular Tubular Medullary Aytpical medullary Mucinous Cribiform Mixed (specify) Other (specify)
SlideReview	LobType	Lobular type	Classical Alveolar Pleomorphic
SlideReview	Tubule	Extent of tubule formation	75% or more of tumour 10-75% of tumour <10% of tumour
SlideReview	NuclearPleo	Extent of nuclear pleomorphism	Small, regular Larger than norm, nucleoli, mod pleo Marked pleo, large nucleoli
SlideReview	Mitotic	Total mitotic figures in 10 high power fields
SlideReview	MitoticTotal	Mitotic score (1, 2 or 3)
SlideReview	Grade	Overall grade
SlideReview	SolidSheet	% of tumour as solid sheet of cells
SlideReview	Circumference	% circumference continuous pushing margin
SlideReview	Necrosis	Confluent necrosis (“Present” or “Absent”)
SlideReview	Infiltrate	Tumour lymphocytic infiltrate	Scant / absent Moderate Prominent
SlideReview	Borders	Tumour cells: presence of discernable cell borders
SlideReview	Vesicular	Tumour cells: presence of vesicular nuclei
SlideReview	EoNucleoli	Tumour cells: presence of prominent eosinophilic nucleoli
SlideReview	DCISMass	% DCIS
SlideReview	DCISExtending	Is the DCIS extending beyond the confines of the main tumour mass
SlideReview	DCISGrade	DCIS nuclear grade	Low Intermediate High
SlideReview	DCISNecrosis	DCIS necrosis	Absent Comedo type Punctate
SlideReview	DCISPolarisation	Presence of DCIS cell polarisation
SlideReview	DCISArchitecture	DCIS architectural pattern (multiple selections)	DCIS Comedo DCIS Cribiform DCIS Papillary DCIS Micropapillary DCIS Solid
SlideReview	LCIS	Presence of LCIS
SlideReview	BRCA1	Is the sample consistent with a BRCA1 phenotype
Slide review has been performed by a pathologist on 214 slides from BRCAX families
TestSensitivity	Gene	Gene tested
TestSensitivity	Sensitivity	Sensitivity of all mutation testing performed on participant	Complete Very High High + MLPA High Moderate Low
See Senstivitities for a description of each test sensitivity category
TissueAliquot	TissueSize	The aliquot size
TissueAliquot	SampleType	Type of sample stored	Archival block Archival tissue Ascites Fresh tissue Pleural effusion RNA later Shavings Slide - stained Slide - unstained
TissueAliquot	Side	Side of the body the tissue was taken from
TissueAliquot	Tumour	Is there tumour present in the aliquot
TissueCollection	TissueType	The type of tissue collected
TissueCollection	DateTaken	The date the tissue was collected
TissueCollection	Prophylactic	Was the tissue removed for prophylactic reasons
TissueCollection	TimeToFrozen	The time taken to freeze the tissue
TissueCollection records details of a surgical collection event. Each collection may be divided into a number of aliquots which are recorded in the TissueAliquot table
Treatment	Treatment	Description of non-cancer-related procedure
Treatment	Reason	Was the treatment cancer-related or prophylactic.
Treatment	StartDate	Date the treatment began
Treatment	EndDate	Date the treatment finished
Treatment	Drug	Treatment drug
Treatment	Dose	Treatment dose

Note that specific data can only be provided for participants who were deceased at time of family enrollment, or who have signed a consent form

The following diagram illustrates the relationship between tables